An observational study in Interstitial Lung Disease (ILD), Chronic Respiratory Diseases and Alpha-1 Antitrypsin Deficiency (AATD), sponsored by Richmond Research Institute. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Richmond Research Institute · Observational
This study is designed for adults who have, or suspected to have, a long-term respiratory (lung) condition such as Alpha-1 Antitrypsin Deficiency (AATD), chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, or interstitial lung disease (ILD).
The aim of the study is to help participants become familiar with the clinical trials unit environment and research team before deciding whether they would like to take part in future clinical trials.
Participants will attend a study visit at the clinical trials unit, where they will receive a guided tour of the facilities and undergo a range of routine health assessments. These may include a review of their medical history, measurements of height, weight, blood pressure and oxygen levels, breathing tests, blood tests, heart tracing (ECG), liver assessment, and questionnaires about their symptoms and quality of life. Some participants may also undergo genetic testing if it is clinically appropriate and previous results are not available.
The information collected will help establish a clinical baseline and improve understanding of how respiratory diseases affect people in everyday life. The study will also explore how symptoms and quality of life relate to clinical measurements and other health information.
Participants will be contacted after their visit to discuss any clinically relevant findings and to answer any questions they may have. If a previously unrecognised condition is identified, participants will be advised appropriately and, with their consent, their GP may be informed to support any further care that may be needed.
The findings from this study may help improve the design of future clinical trials and support the development of more patient-centred research.
This study is designed for adults who have, or suspected to have, a long-term respiratory (lung) condition such as AATD, COPD, asthma, bronchiectasis, or ILD.
This study will help participants become familiar with the clinical trials unit environment and research team. The findings from this study may help improve the design of future clinical trials and support the development of more patient-centred research.
This is a participant engagement study and will take about 5 weeks to complete. There is no overnight stay, and no investigational drug will be given.
The study involves two visits; Visit 1: An in-person engagement visit (Day 1) and Visit 2: A follow-up about 3 weeks (±14 days) after Day 1.
During the Day 1 visit, participants will be asked to provide written informed consent. After providing consent, participants will be given a tour of the clinical study unit to get familiar with the environment and facilities. Following informed consent on Day 1, participants will undergo a unit tour and undergo a range of routine health assessments. These may include a review of their medical history, measurements of height, weight, blood pressure and oxygen levels, breathing tests, blood tests, heart tracing (ECG), liver assessment, and questionnaires about their symptoms and quality of life. Some participants may also undergo genetic testing if it is clinically appropriate and previous results are not available.
A Follow-Up with the Study Doctor will be conducted within 3 weeks (±14 days) after Day 1 to discuss the results of the clinical assessments. The participants will have the opportunity to ask any further questions. If a participant has a confirmed new genetic or respiratory diagnosis and they are not already receiving appropriate care from a specialist, they will be provided with appropriate counselling regarding the finding and, where clinically indicated, their General Practitioner (GP) will be informed to support ongoing clinical management and will be referred to an appropriate specialist.
680 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.
This study's planned enrollment of 500 is above the median of 157 across 278 observational studies indexed under Lung Diseases, Interstitial.
Browse Lung Diseases, Interstitial studies →Richmond Research Institute is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult participants aged 18 years or older with a confirmed or suspected chronic respiratory disease, including alpha-1 antitrypsin deficiency, chronic obstructive pulmonary disease, asthma, bronchiectasis, interstitial lung disease or other chronic respiratory conditions considered appropriate by the Investigator and Sponsor, who are considering participation in future relevant clinical trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of patients indicating willingness to be re-contacted for future clinical trials
Time frame: Until the end of the study (up to 5 weeks)]
Participation feedback questionnaire results using Participant Feedback and Clinical Research Experience Questionnaire
Time frame: Until the end of the study (up to 5 weeks)]
Clinical baseline characterisation of medical history
Time frame: Day 1
Clinical baseline characterisation of exacerbation history
Time frame: Day 1
Clinical baseline characterisation of smoking status
Time frame: Day 1
Clinical baseline characterisation of concomitant medications (con-meds)
Time frame: Day 1
Clinical baseline characterisation of respiratory rate
Time frame: Day 1
Clinical baseline characterisation of body temperature
Time frame: Day 1
Clinical baseline characterisation of pulse rate
Time frame: Day 1
Clinical baseline characterisation of oxygen saturation
Time frame: Day 1
Clinical baseline characterisation of blood pressure
Time frame: Day 1
Clinical baseline characterisation of Lung function for FEV1 parameter
Time frame: Day 1
Clinical baseline characterisation of Lung function for FVC parameter
Time frame: Day 1
Clinical baseline characterisation of Lung function for FEV1/FVC ratio
Time frame: Day 1
Clinical baseline characterisation of oxygen use
Time frame: Day 1
Clinical baseline characterisation of bloods including genetic testing where clinically indicated and imaging data where available.
Time frame: Day 1
Number and proportion of new diagnoses following assessment
Time frame: Until the end of the study (up to 5 weeks)]
Factors associated with underdiagnosis by exploring differences between patient-reported outcomes and clinical data, including potential variations by age, sex and ethnicity
Time frame: Until the end of the study (up to 5 weeks)]
Differences in patient-reported outcome scores between chronic respiratory disease subgroups using EQ-5D-5L together with the EQ Visual Analogue Scale (EQ VAS)
Time frame: Until the end of the study (up to 5 weeks)]
Plan to share: No — Sharing of personal data with other organisations is not planned.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.
Of 132 observational studies under Lung Diseases, Interstitial, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's planned 9 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Richmond Research Institute